ATE493129T1 - Depot formulierungen von iloperidone und einem sternförmigen polymer - Google Patents

Depot formulierungen von iloperidone und einem sternförmigen polymer

Info

Publication number: ATE493129T1
Authority: AT; Austria
Prior art keywords: iloperidone; star; shaped polymer; depot formulations; polymer
Prior art date: 2001-10-30

Application number

AT02785330T

Other languages

English (en)

Inventor

Markus Ahlheim

Rolf Loeffler

Original Assignee

Novartis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-10-30

Filing date

2002-10-29

Publication date

2011-01-15

2002-10-29 Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh

2011-01-15 Application granted granted Critical

2011-01-15 Publication of ATE493129T1 publication Critical patent/ATE493129T1/de

Links

XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 title abstract 2
229960003162 iloperidone Drugs 0.000 title abstract 2
239000000203 mixture Substances 0.000 title abstract 2
229920000642 polymer Polymers 0.000 title abstract 2
VIQCGTZFEYDQMR-UHFFFAOYSA-N fluphenazine decanoate Chemical compound C1CN(CCOC(=O)CCCCCCCCC)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 VIQCGTZFEYDQMR-UHFFFAOYSA-N 0.000 title 1
229920000249 biocompatible polymer Polymers 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
229920000728 polyester Polymers 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Dermatology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Materials For Medical Uses (AREA)

AT02785330T 2001-10-30 2002-10-29 Depot formulierungen von iloperidone und einem sternförmigen polymer ATE493129T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33903601P	2001-10-30	2001-10-30
PCT/EP2002/012073 WO2003037337A1 (en)	2001-10-30	2002-10-29	Depot formulations of iloperidone and a star polymer

Publications (1)

Publication Number	Publication Date
ATE493129T1 true ATE493129T1 (de)	2011-01-15

Family

ID=23327202

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02785330T ATE493129T1 (de)	2001-10-30	2002-10-29	Depot formulierungen von iloperidone und einem sternförmigen polymer

Country Status (11)

Country	Link
US (2)	US7767230B2 (de)
EP (2)	EP2295058B1 (de)
JP (1)	JP5067998B2 (de)
CN (2)	CN101912367A (de)
AT (1)	ATE493129T1 (de)
BR (1)	BRPI0213564B8 (de)
CA (1)	CA2463158C (de)
CY (1)	CY1111357T1 (de)
DE (1)	DE60238780D1 (de)
ES (2)	ES2436439T3 (de)
WO (1)	WO2003037337A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100591767B1 (ko) *	1999-09-09	2006-06-23	더 리젠츠 오브 더 유니버시티 오브 캘리포니아	탁산의 맥관형성 혈관 전달을 위한 양이온성 리포좀
BRPI0213564B8 (pt) *	2001-10-30	2021-05-25	Novartis Ag	formulação depósito e micropartícula compreendendo iloperidona e polímero poli(d,l-lactídeo-co-glicolídeo), e processo para preparação da referida micropartícula
GB0216416D0 (en) *	2002-07-15	2002-08-21	Novartis Ag	Organic compounds
US20100063093A1 (en)	2007-03-28	2010-03-11	Curt Wolfgang	Methods for the administration of iloperidone
WO2006039663A2 (en)	2004-09-30	2006-04-13	Vanda Pharmaceuticals, Inc	Methods for the administration of iloperidone
DE102005051342A1 (de) *	2005-10-25	2007-04-26	Goldschmidt Gmbh	Verkapselung und kontrollierte Freisetzung biologisch aktiver Wirkstoffe mit enzymatisch abbaubaren hyperverzweigten Trägerpolymeren
PL1940905T3 (pl)	2005-10-25	2011-02-28	Evonik Degussa Gmbh	Preparaty zawierające hiperrozgałęzione polimery
US20090306137A1 (en)	2006-05-22	2009-12-10	Wolfgang Curt D	Treatment for depressive disorders
CN100460441C (zh) *	2006-09-25	2009-02-11	南开大学	生物可降解星型结构聚乙丙交酯载药微球及其制备方法
CA2667890C (en)	2006-10-31	2015-01-27	Surmodics Pharmaceuticals, Inc.	Spheronized polymer particles
CA2698534C (en) *	2007-09-10	2018-10-09	Vanda Pharmaceuticals, Inc.	Prediction of qt prolongation based on snp genotype
EP2222301B1 (de)	2007-12-13	2014-10-08	Vanda Pharmaceuticals Inc.	Verfahren und zusammensetzung zur behandlung einer erkrankung, die durch den alpha-adrenozeptor vermittelt wird
WO2009076664A1 (en)	2007-12-13	2009-06-18	Vanda Pharmaceuticals Inc.	Method and composition for treating a serotonin receptor-mediated condition
US20120136050A1 (en)	2009-07-16	2012-05-31	Vanda Pharmaceuticals Inc.	Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
BR112012015084A2 (pt) *	2009-12-23	2017-03-07	Lupin Ltd	composição farmacêutica de liberação lenta de iloperidone
CN102311430A (zh) *	2010-06-29	2012-01-11	大道隆达（北京）医药科技发展有限公司	伊潘立酮的新晶态及其制备方法
WO2012123963A2 (en) *	2011-02-24	2012-09-20	Megafine Pharma (P) Ltd.	A process for preparation of iloperidone and amorphous co- precipitate of iloperidone with pharmaceutically acceptable excipient
US11918557B2 (en)	2012-01-26	2024-03-05	Vanda Pharmaceuticals Inc.	Treatment of circadian rhythm disorders
KR102593047B1 (ko)	2012-01-26	2023-10-24	반다 파마슈티칼즈, 인코퍼레이티드.	일주기 리듬 장애의 치료
JP5959083B2 (ja)	2012-05-18	2016-08-02	ヴァンダファーマシューティカルズインコーポレイテッド	（１Ｒ−ｔｒａｎｓ）−Ｎ−［［２−（２，３−ジヒドロ−４−ベンゾフラニル）シクロプロピル］メチル］プロパンアミドの代謝物
WO2014100292A1 (en)	2012-12-18	2014-06-26	Vanda Pharmaceuticals Inc.	Treatment of circadian rhythm disorders
US10376487B2 (en)	2013-11-12	2019-08-13	Vanda Pharmaceuticals Inc.	Method of treatment
US11090285B2 (en)	2013-11-12	2021-08-17	Vanda Pharmaceuticals Inc	Treatment of circadian rhythm disorders
CN103599074A (zh) *	2013-11-26	2014-02-26	重庆医药工业研究院有限责任公司	一种伊潘立酮缓释微球及其制备方法
CN104352443A (zh) *	2014-10-21	2015-02-18	河北科技大学	伊潘立酮缓释微球及其制备方法
ES2870498T3 (es)	2015-02-17	2021-10-27	Vanda Pharmaceuticals Inc	Iloperidona para el tratamiento de esquizofrenia
US11071728B2 (en)	2015-12-11	2021-07-27	Vanda Pharmaceuticals Inc.	Treatment of schizophrenia
BR112021009265A2 (pt) *	2018-12-04	2021-08-10	Vanda Pharmaceuticals Inc.	métodos para preparar e administrar uma formulação de depósito injetável de iloperidona cristalina, e, formulação de depósito injetável de iloperidona cristalina
GB201900258D0 (en)	2019-01-08	2019-02-27	Medincell	Pharmaceutical composition
US11607408B2 (en)	2019-10-15	2023-03-21	Vanda Pharmaceuticals Inc.	Method of treatment of schizophrenia
AU2023408198A1 (en)	2022-12-19	2025-05-29	Vanda Pharmaceuticals Inc.	Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH656884A5 (de)	1983-08-26	1986-07-31	Sandoz Ag	Polyolester, deren herstellung und verwendung.
DE3511587A1 (de) *	1985-03-27	1986-10-02	Schering AG, Berlin und Bergkamen, 1000 Berlin	Glykoester des estradiols und estriols
US4886370A (en)	1987-08-25	1989-12-12	Nkk Corporation	Method for detecting a state of substance existing in pipe
US5776963A (en) *	1989-05-19	1998-07-07	Hoechst Marion Roussel, Inc.	3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5364866A (en)	1989-05-19	1994-11-15	Hoechst-Roussel Pharmaceuticals, Inc.	Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
DE69021645T2 (de) *	1989-05-19	1996-02-22	Hoechst-Roussel Pharmaceuticals Inc., Somerville, N.J.	N-(aryloxyalkyl)heteroarylpiperidine und -heteroarylpiperazine, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente.
US5538739A (en)	1989-07-07	1996-07-23	Sandoz Ltd.	Sustained release formulations of water soluble peptides
ES2098358T3 (es) *	1990-06-04	1997-05-01	Schering Corp	Metodo para preparar cristales de interferon alfa-2.
CN1074923C (zh)	1993-11-19	2001-11-21	詹森药业有限公司	微囊密封的3-哌啶基取代的1,2-苯并异唑类和1,2-苯并异噻唑类
WO1998054186A1 (en)	1997-05-26	1998-12-03	Akzo Nobel N.V.	Salts of aromatic sulphonic acids
UA72189C2 (uk) *	1997-11-17	2005-02-15	Янссен Фармацевтика Н.В.	Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US5955459A (en) *	1997-11-26	1999-09-21	Neuromedica, Inc.	Fatty acid-antipsychotic compositions and uses thereof
US6541606B2 (en) *	1997-12-31	2003-04-01	Altus Biologics Inc.	Stabilized protein crystals formulations containing them and methods of making them
DE19816070A1 (de)	1998-04-09	1999-10-14	Aventis Res & Tech Gmbh & Co	Retardtablette hergestellt aus linearen wasserunlöslichen Polysacchariden
WO2000023057A2 (en) *	1998-10-16	2000-04-27	Janssen Pharmaceutica N.V.	Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition
JP2003535106A (ja)	2000-06-02	2003-11-25	ノボノルディスクアクティーゼルスカブ	グルコース検知性インスリン誘導体からの、インスリンのグルコース依存性放出
JP2005504783A (ja)	2001-08-31	2005-02-17	ノバルティスアクチエンゲゼルシャフト	イロペリドン代謝産物の光学異性体
BRPI0213564B8 (pt) *	2001-10-30	2021-05-25	Novartis Ag	formulação depósito e micropartícula compreendendo iloperidona e polímero poli(d,l-lactídeo-co-glicolídeo), e processo para preparação da referida micropartícula
GB0216416D0 (en)	2002-07-15	2002-08-21	Novartis Ag	Organic compounds

2002
- 2002-10-29 BR BRPI0213564A patent/BRPI0213564B8/pt not_active IP Right Cessation
- 2002-10-29 AT AT02785330T patent/ATE493129T1/de active
- 2002-10-29 JP JP2003539681A patent/JP5067998B2/ja not_active Expired - Lifetime
- 2002-10-29 EP EP10009932.4A patent/EP2295058B1/de not_active Expired - Lifetime
- 2002-10-29 WO PCT/EP2002/012073 patent/WO2003037337A1/en not_active Ceased
- 2002-10-29 CN CN2010102694146A patent/CN101912367A/zh active Pending
- 2002-10-29 CA CA2463158A patent/CA2463158C/en not_active Expired - Lifetime
- 2002-10-29 ES ES10009932.4T patent/ES2436439T3/es not_active Expired - Lifetime
- 2002-10-29 DE DE60238780T patent/DE60238780D1/de not_active Expired - Lifetime
- 2002-10-29 CN CNA028214269A patent/CN1578664A/zh active Pending
- 2002-10-29 ES ES02785330T patent/ES2358416T3/es not_active Expired - Lifetime
- 2002-10-29 EP EP02785330A patent/EP1441727B1/de not_active Expired - Lifetime
- 2002-10-30 US US10/283,989 patent/US7767230B2/en not_active Expired - Lifetime
2010
- 2010-05-20 US US12/784,251 patent/US8815293B2/en not_active Expired - Lifetime
2011
- 2011-03-28 CY CY20111100327T patent/CY1111357T1/el unknown

Also Published As

Publication number	Publication date
US8815293B2 (en)	2014-08-26
WO2003037337A8 (en)	2004-05-13
WO2003037337A1 (en)	2003-05-08
EP2295058A1 (de)	2011-03-16
CA2463158C (en)	2013-07-30
CY1111357T1 (el)	2015-08-05
CN1578664A (zh)	2005-02-09
EP2295058B1 (de)	2013-09-04
HK1068263A1 (en)	2005-04-29
BR0213564A (pt)	2004-08-31
US20100233217A1 (en)	2010-09-16
DE60238780D1 (de)	2011-02-10
BRPI0213564B1 (pt)	2016-08-02
CA2463158A1 (en)	2003-05-08
EP1441727A1 (de)	2004-08-04
JP5067998B2 (ja)	2012-11-07
US20030091645A1 (en)	2003-05-15
ES2358416T3 (es)	2011-05-10
US7767230B2 (en)	2010-08-03
CN101912367A (zh)	2010-12-15
HK1155381A1 (en)	2012-05-18
EP1441727B1 (de)	2010-12-29
JP2005508975A (ja)	2005-04-07
ES2436439T3 (es)	2014-01-02
BRPI0213564B8 (pt)	2021-05-25

Legal Events

Date

Code

Title

Description

2011-07-15

UEP

Publication of translation of european patent specification

Ref document number: 1441727

Country of ref document: EP

Publication	Publication Date	Title
ATE493129T1 (de)	2011-01-15	Depot formulierungen von iloperidone und einem sternförmigen polymer
DE60235083D1 (de)	2010-03-04	Substituierte tetracyclin-verbindungen zur behandlung von malaria
ATE282653T1 (de)	2004-12-15	Saure polymilchsäure polymere
DE69812946D1 (de)	2003-05-08	Ethylenpolymerzusammensetzungen und daraus hergestellte gegenstände
DE69728307D1 (de)	2004-05-06	Absorbierbare polymer Mischungen und chirurgische Gegenstände daraus
EP1852437A3 (de)	2008-03-12	42-O-Alkoxyalkyl-Rapamycin-Derivate und Zusammensetzungen damit
EP1233956A4 (de)	2006-07-05	Bryostatin analoga, synthetische methoden und verwendungen
DE69626589D1 (de)	2003-04-17	Polymer, Verfahren zur Herstellung, Haarbehandlungszusammensetzungen und kosmetische Zusammensetzungen
DE60144375D1 (de)	2011-05-19	7-, 8- und 9-substitutierte tetracyclinverbindungen
DE69923359D1 (de)	2005-02-24	Zusammensetzungen und daraus hergestellte gegenstände
ATE296642T1 (de)	2005-06-15	Reverse-phase zusamensetzung zur bindegewebsreparatur
WO2004042797A3 (en)	2005-07-07	Sacrificial compositions, methods of use thereof, and methods of decomposition thereof
ATE353675T1 (de)	2007-03-15	Kationische-alkid-polyester für medizinische anwendungen
GR940100055A (el)	1994-10-31	Πολυμερή καστορέλαιου.
DE60322824D1 (de)	2008-09-25	Funktionalisierte Alkydpolyesterpolymere zur medizinischen Verwendung
ID15948A (id)	1997-08-21	Komposisi-komposisi insektisida berdasarkan polimer-polimer
DE60020206D1 (de)	2005-06-23	Zusammensetzung und Verfahren zur Herstellung von dehnbaren Polymeren und dadurch geformte Gegenstände
DE60214853D1 (de)	2006-11-02	Biologisch abbaubare kaugummigrundmasse
EP2377519A3 (de)	2011-11-23	Arzneimittel enthaltend Octreotidmikropartikel
DE60120416D1 (de)	2006-07-20	Polyaminoestern und deren verwendung zur herstellung von dentalmassen
DE19882607T1 (de)	2000-07-27	Verfahren zur Herstellung von Olefinpolymeren oder -copolymeren sowie Olefinpolymere oder -copolymere und Anwendungen davon
DE69132415D1 (de)	2000-10-19	Umweltfreundliche Polymerzusammensetzungen sowie Anwendungen desselben
DE69705108D1 (de)	2001-07-12	Mischungen ausgehend von eugenia jambolana lamarck samen, herstellung und verwendung solcher mischungen sowie einiger inhaltsstoffe als medikamente
ATE214293T1 (de)	2002-03-15	Knochenimplantat
DE60234756D1 (de)	2010-01-28	Konjugierte homo- und copolymere enthaltend substituierte oder unsubstituierte heteroaryleinheiten, herstellung und verwendung